Detail akcie Oxford Biomedica Rg online

Business Summary: Oxford Biomedica PLC is a contract development and manufacturing organization (CDMO) in cell and gene therapy. It provides viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. It offers several technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. It has bioprocessing and manufacturing facilities across Oxfordshire, United Kingdom, Lyon and Strasbourg, France and near Boston, MA, United Sates. Its Platform segment is involved in bioprocessing and process development activities undertaken for third parties. Its Viral Vector includes LentiVector platform, inAAVate platform, and Other Viral Vectors. Its LentiVector platform technology is an advanced lentiviral vector-based gene delivery system.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Oxford BioMedica plc revenues increased 18% to L50.8M. Net loss decreased 32% to L32.5M. Revenues reflect United Kingdom segment increase from L1.3M to L4.7M, United States of America segment increase of 8% to L31.9M. Lower net loss reflects Research and development costs decrease of 50% to L15.8M (expense), Bioprocessing costs decrease of 22% to L23.6M (expense).